Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
WATERTOWN, Mass. , Nov. 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements
WATERTOWN, Mass. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the third quarter ended
View HTML
Toggle Summary Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer
WATERTOWN, Mass. , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the appointment of Kamalam (Kam) Unninayar as
View HTML
Toggle Summary Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017
- Company plans to advance current oral eravacycline formulation into a phase 2 study in 1H18 -
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Data at IDWeek 2017
WATERTOWN, Mass. , Sept. 25, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced upcoming data presentations at Infectious
View HTML
Toggle Summary Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections
- Top-line Data Expected in 1Q 2018 - - IGNITE3 Results to Support U.S. sNDA Filing for IV Eravacycline in cUTI - WATERTOWN, Mass. , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
WATERTOWN, Mass. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will present at the
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency
WATERTOWN, Mass. , Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results and Highlights Recent Achievements
WATERTOWN, Mass. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the second quarter ended
View HTML
Toggle Summary Tetraphase Announces Pricing of Public Offering of Common Stock
WATERTOWN, Mass. , July 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the pricing of an underwritten public offering
View HTML